Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 130,867

Document Document Title
WO/2018/187467A1
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes or a sterile fecal filtrate for ...  
WO/2018/185468A1
The invention provides genetic constructs and recombinant vectors comprising such constructs. The constructs and vectors can be used in gene therapy methods for the treatment, prevention or amelioration of a neurodegenerative disorder, i...  
WO/2018/186421A1
The present invention addresses the problem of providing a cell population which includes mesenchymal cells showing low cell aggregation and is useful for the intravenous administration of a cell preparation, a production method therefor...  
WO/2018/184585A1
The present invention provides a compound for inhibiting IDO, a manufacturing method and a use thereof. The compound has a general structural formula of (I), wherein (II) is selected from a cis-isomer, a trans-isomer, or a mixture of cis...  
WO/2018/184059A1
There are described methods for the prophylaxis or treatment of pain in a mammal wherein the method comprising administering to the mammal an effective amount of a pain inhibitor comprising a pain inhibiting peptide having an amino acid ...  
WO/2018/184316A1
Provided is a nano-nemifitide liquid phase preparation method comprising the following steps: 1) preparing intermediate 1H-Trp(Boc)-NH-Dpm with Dpm-NH2 and Fmoc-Trp(Boc)-OH; 2) preparing intermediate 2H-Gly-Trp(Boc)-NH-Dpm; 3) preparing ...  
WO/2018/187428A1
The invention is directed to a cell culture medium composition wherein the composition comprises an effective amount of: valproic acid; a GSK-3 inhibitor; a TGFPRI inhibitor; Forskolin; a JNK inhibitor; a protein kinase C (PKC) inhibitor...  
WO/2018/187647A1
Provided herein are uses of pharmaceutically effective amounts of HASF and/or of compounds that increases endogenous expression of HASF in the treatment of a neurological disease, disorder, or condition. Also provided are methods for tre...  
WO/2018/184561A1
Disclosed in the present invention are compounds having an aldolase selective inhibiting activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds in preparation of drugs fo...  
WO/2018/186441A1
The present invention provides a risperidone-containing patch endowed with both excellent drug releasability and patch physical properties. Specifically, the present invention provides a medical patch that includes risperidone or a pharm...  
WO/2018/187350A1
Methods of treatment of progressive supranuclear palsy or its symptoms, with PPARγ agonists, and in particular, the compound of formula (I) known as INT 131: Formula (I). Also provided are methods of treating a subject that include sele...  
WO/2018/187606A1
Methods of modulating the interaction between β-amyloid and α7-nAChR are provided. Aspects of the methods include administering to the subject an effective amount of a naphthalene derivative active agent. Compositions and kits for prac...  
WO/2018/186366A1
The present invention addresses the problem of providing a novel cyclin-dependent kinase 8 and/or 19 inhibitor that is useful as an anticancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor that c...  
WO/2018/184706A1
The current invention concerns an innovative treatment for mitochondrial disorders and diseases or conditions associated with mitochondrial dysfunction. In particular, effective and safe dosages of compounds suitable for the treatment of...  
WO/2018/184590A1
Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring ...  
WO/2018/186418A1
The present invention addresses the problem of providing a cell population which includes attached cells derived from fetal appendages and has a low differentiation potential, a production method therefor, and a pharmaceutical compositio...  
WO/2018/186770A1
The invention relates to the chemical and pharmaceutical industry. Proposed is a use of synthetic peptides as specific clathrin inhibitors. Also proposed is a method for preventing or treating a disease or condition in an animal, compris...  
WO/2018/186492A1
Provided are a non-REM sleep promoter and a food composition for promoting non-REM sleep. The non-REM sleep promoter and the food composition for promoting non-REM sleep contain a euglena-derived material as an active ingredient, and pro...  
WO/2018/186032A1
The present invention provides an anticancer agent based on a novel mechanism. Specifically, the present invention relates to an inhibitor that inhibits gene expression regulation by SWI/SNF complex-dependent NF-κB or corepressor comple...  
WO/2018/181859A1
The present invention addresses the problem of providing a compound which can be used for the treatment or prevention of peripheral neuropathy induced by an anticancer agent. The present invention provides a therapeutic agent or a prophy...  
WO/2018/181986A1
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...  
WO/2018/181380A1
To provide an edible composition for intestinal bacteria which ameliorates intestinal flora (intestinal bacterial flora) and promotes the diversity thereof so as to contribute to human health. A composition comprising: a natural dietary ...  
WO/2018/177114A1
The new compound provided by the applicant is a salicylic acid-based fumarate derivative having a general structural formula (A): wherein in the general structural formula (A), R1 is one of H+, Na+, K+ or NH4+, and R2 is an esterified pr...  
WO/2018/178670A1
A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second as...  
WO/2018/178029A1
The present invention relates to a method for treating degenerative muscular and/or neurological conditions or diseases. The inventors found that SIRT3 is decreased with age in human striated muscles which are post-mitotic cells. More pa...  
WO/2018/178384A1
The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic h...  
WO/2018/177693A1
The present invention relates to sulphated disaccharides of formula (I) for use in the treatment of neuropathic pain. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I) and at least ...  
WO/2018/178237A1
The invention relates to a method for treating mitochondrial genetic diseases. The inventors have worked with primary fibroblasts from patients and control individuals and collected protein lysates for western blotting. Importantly, they...  
WO/2018/177232A1
The present invention provides a complex of formula (I) or a solvate thereof, wherein n is 1 to 4. The present invention also provides a pharmaceutical composition and an application of the pharmaceutical composition in preventing or tre...  
WO/2018/181345A1
Provided is a compound which has an Nrf2-activating activity and is expected to be useful as a prophylactic or therapeutic agent for diseases associated with oxidative stress, particularly hepatitis (e.g., non-alcoholic steatohepatitis (...  
WO/2018/178852A1
The present invention relates to methods of treating multiple sclerosis, amyotrophic lateral sclerosis (ALS) or Alzheimer`s disease in a subject in need of treatment thereof by administering an effective amount of 4-(2-((1R,2R)-2-hydroxy...  
WO/2018/178030A1
The present invention relates to a method for treating degenerative muscular and/or neurological conditions or diseases. The inventors found that TRF2 is decreased with age in human striated muscles which are post-mitotic cells. More par...  
WO/2018/182495A1
A tolerogenic composition for use in a method of treatment for multiple sclerosis (MS) in a MS patient exhibiting T-cell autoreactivity against an endogenous epitope corresponding to a T-cell epitope comprised in the amino-acid sequence ...  
WO/2018/181860A1
The present invention addresses the problem of providing a compound used for treatment or prevention of peripheral neuropathies. Provided is a therapeutic or prophylactic agent for peripheral neuropathies, the agent containing, as an act...  
WO/2018/182639A1
The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAO...  
WO/2018/178950A1
Dosage regimens of anti-α-synuclein antibodies are provided. These dosage regimens find use in the treatment of synucleinopathies such as Parkinson's disease (PD), Parkinson's Disease Dementia (PDD), dementia with Lewy bodies (DLB), Lew...  
WO/2018/183264A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdo...  
WO/2018/183151A1
The present invention relates to topical compositions containing a therapeutically effective amount of tetrahydrocannabinol. The compositions are useful for treating a patient suffering from conditions such as pain and pruritus, particul...  
WO/2018/179343A1
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...  
WO/2018/176343A1
Compounds of Formula (A), where the definition of the variables are as described in the description, as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as modulators of dysfun...  
WO/2018/183097A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disor...  
WO/2018/178141A1
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solv...  
WO/2018/180005A1
The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. This antisense oligonucleotide has at least one modified nucleotide that inhibits expression of chondroitin sulfate N-acetylg...  
WO/2018/181135A1
Provided are: a method for producing a learning effectiveness-improving agent and a learning effectiveness-improving food product composition which are capable of improving learning effectiveness in normal situations where physical or ps...  
WO/2018/183800A1
Disclosed are substituted (4'-hydroxylphenyl)cycloalkane compounds and substituted (4'-hydroxylphenyl)cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be ...  
WO/2018/181456A1
Provided is a compound represented by the formula, or a salt thereof, the compound having RORγt-inhibiting activity and being useful as a prophylactic or therapeutic agent for autoimmune or allergic diseases.  
WO/2018/176098A1
Provided in accordance with the present disclosure are methods for preventing or reducing cognitive dysfunction or decline associated with an acquired brain injury, for treating cognitive dysfunction or decline associated with an acquire...  
WO/2018/178944A1
The present invention relates to amino pyrazine purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to 5-(2-(8-Oxa-3-azabicyclo[octan- 3-yl)-9-(pentan-3-yl)-9H-purine-6-yl)pyrazin-2-ami...  
WO/2018/176150A1
Novel methods for isolating fish roe/egg extracts, notably a coagulum and a sediment extract, enriched in phospholipids and omega-3 fatty acids are described. Novel compositions comprising omega-3 polyunsaturated fatty acids and micronut...  
WO/2018/178938A1
The disclosures herein relate to novel compounds of formula (IA) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associat...  

Matches 1 - 50 out of 130,867